Recon: Novartis bags EU authorization for CML drug Scemblix; AZ’s Farxiga cuts death risk for heart failure patients
ReconJoanne S. Eglovitch
BiologicsBiotechnologyDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy